Can a malaria drug help wipe out breast Cancer's hidden seeds?
NCT ID NCT04523857
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether two oral drugs, abemaciclib (a targeted cancer therapy) and hydroxychloroquine (an older malaria drug), can eliminate leftover cancer cells hiding in the bone marrow of breast cancer patients. About 44 people with a history of breast cancer and detectable residual cells will take one or both pills twice daily for six cycles. The goal is to see if the combination is safe and can clear these cells, which may lower the chance of the cancer returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib (Verzenio) and hydroxychloroquine (Plaquenil)
What this could lead to
If successful, this could show a way to clear leftover cancer cells in the bone marrow, potentially reducing the risk of breast cancer recurrence.
What could go wrong
This is a small, early-phase trial with only 44 participants, so results may not apply broadly. The combination of drugs may cause side effects, and it's not yet known if clearing these cells will actually prevent cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••